Literature DB >> 679176

Differential response of cultured mouse mammary cells of varying tumorigenicity to cytochalasin B.

M R Steiner, B Altenburg, C S Richards, J P Dudley, D Medina, J S Butel.   

Abstract

Cultured BALB/c mouse mammary gland epithelial cells of varying oncogenic potential in vivo have been examined for their ability to multinucleate in the presence of cytochalasin B (CB). Highly tumorigenic cell lines derived from mammary tumors with hormonal, viral, or chemical carcinogen etiologies were extensively multinucleated when cultured in CB-supplemented medium. Normal mammary gland cells from either pregnant or lactating animals were predominantly mono- or binucleate under comparable conditions. At low passage levels after cloning, cell lines derived from a chemical carcinogen-induced mammary tumor were weakly oncogenic and remained largely mono-, or binucleated when cultured in CB-supplemented medium. At higher cell passage levels, both the ability to produce tumors in vivo and the degree of multinucleation in CB-supplemented medium increased dramatically with the clonal cell lines. Thus, the response of cultured mouse mammary gland epithelial cells to CB in vitro may be useful as a marker of the oncogenic potential of such cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679176

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Chemical carcinogen-mouse mammary tumor virus interactions in cell transformation.

Authors:  D K Howard; J Schlom; P B Fisher
Journal:  In Vitro       Date:  1983-01

2.  Characterization of a 7,12-dimethylbenz(alpha)anthracene-induced BALB/c mouse mammary tumor epithelial cell line.

Authors:  J P Dudley; D Medina; J S Butel
Journal:  In Vitro       Date:  1980-11

3.  Chemotherapy in vivo against M109 murine lung carcinoma with cytochalasin B by localized, systemic, and liposomal administration.

Authors:  Matthew Trendowski; Joan M Mitchell; Christine M Corsette; Christopher Acquafondata; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-01-06       Impact factor: 3.850

4.  Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models.

Authors:  Matthew Trendowski; Joan M Mitchell; Christine M Corsette; Christopher Acquafondata; Thomas P Fondy
Journal:  Invest New Drugs       Date:  2015-01-07       Impact factor: 3.850

5.  Using cytochalasins to improve current chemotherapeutic approaches.

Authors:  Matthew Trendowski
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

6.  Preparation, In Vivo Administration, Dose-Limiting Toxicities, and Antineoplastic Activity of Cytochalasin B.

Authors:  Matthew Trendowski; Joseph N Zoino; Timothy D Christen; Christopher Acquafondata; Thomas P Fondy
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

7.  Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.

Authors:  Matthew Trendowski; Timothy D Christen; Christopher Acquafondata; Thomas P Fondy
Journal:  BMC Cancer       Date:  2015-09-10       Impact factor: 4.430

8.  Inhibition of DNA synthesis in adrenocortical cells by cytochalasin B.

Authors:  M A McPherson; J Ramachandran
Journal:  J Cell Biol       Date:  1980-07       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.